Inhaled KB707 monotherapy achieves 27% ORR in advanced NSCLC; updated to 36%

Krystal Biotech, Inc.

27% ORR (3/11 PR) in heavily pre-treated NSCLC; extended follow-up yields 36% (4/11 PR).
Median DOR and PFS not reached; responses durable.
Safety well-tolerated: most TRAEs Grade 1/2, no Grade 4/5; MTD not reached.
Combination cohort with pembrolizumab enrolling for NSCLC.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.